Mechanistically, oncogenic activation of RAS/RAF/ERK signaling is one of the mechanisms that enhance proteasome capacity, while treatment with PI causes the phosphorylation of AKT [59,60], and both mechanisms contribute to the resistance to proteasome inhibition in myeloma cells. Here, AKT1 is linked to plasma cell myeloma.